The stem cell-transplant technology developer, partly based on Stanford research, is going public through a reverse merger that will give it a $490m market capitalisation.
Jasper Therapeutics, a US-based stem cell-transplant technology developer partly based on research at Stanford University, has agreed to a reverse merger with special purpose acquisition company Amplitude Healthcare Acquisition Corp.
The company will acquire the listing on the Nasdaq Capital Market obtained by Amplitude in a $100m initial public offering in November 2019. The deal will grant the merged company an initial market capitalisation of approximately $490m.
The reverse merger deal is backed by $100m private investment in…
